Navigation Links
Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium
Date:11/6/2008

8 (p < 0.0001) and 20.7 at Week 16 (p = 0.02). Immune monitoring performed in three of four patients who underwent repeat treatment suggested an increase in immune response following the booster treatments. Five patients had prolonged disease stabilization ranging from 48 to 94 weeks, without the addition of other cancer therapy other than the continuation of bisphosphonates. In addition, one patient experienced a partial response lasting approximately six months.

"We were pleased to see consistent results across both NEUVENGE trials, particularly as they further substantiate the tolerability of this therapeutic approach," stated Mark Frohlich, M.D., senior vice president, clinical affairs and chief medical officer. "These data provide further evidence of the promise of our active cellular immunotherapy platform which also includes PROVENGE(R) (sipuleucel-T), our lead product candidate currently in late-stage development for prostate cancer. We expect to receive the final data analysis from our ongoing Phase 3 PROVENGE trial in mid-2009 and look forward to discussing further clinical development plans for NEUVENGE and our immunotherapy pipeline after that time."

About NEUVENGE

NEUVENGE (lapuleucel-T) is an investigational product in a new class of active cellular immunotherapies (ACIs) that are uniquely designed to stimulate a patient's own immune system. ACIs hold promise because they may provide patients with a meaningful clinical benefit with low toxicities. NEUVENGE is designed to stimulate cellular immune responses against HER2/neu. HER2/neu is over-expressed in a variety of solid tumors, including breast, colorectal, bladder and ovarian cancer. In clinical studies, patients typically received three infusions over a one-month period as a complete course of therapy.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commerc
'/>"/>

SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
3. Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
4. Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia
5. Dendreon Initiates Phase 2 Trial of PROVENGE in Patients With Localized Prostate Cancer Prior to Surgery
6. Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October
7. Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial
8. Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial
9. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
10. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
11. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... YORK and LONDON , ... of market intelligence, MarketResearch.com is pleased to announce the ... and Consultancy focusing on the active pharmaceutical ingredient (API) ... visit: http://www.marketresearch.com/land/publisher.asp?vendorid=4023&progid=86891 . In IQ4I,s ... – Forecast to 2020 , IQ4I ...
(Date:11/26/2014)... YORK , Nov. 25, 2014  Medtronic,s ... Covidien has been widely discussed in the ... it,s also creating a stronger leading player in ... to Kalorama Information.  The healthcare market research firm ... systems will feature a diverse set of solutions ...
(Date:11/26/2014)... 2014  Breckenridge Pharmaceutical, Inc. announced today that ... with Pii (Pharmaceutics International, Inc.) ( Hunt ... Pii expect to develop and commercialize several new ... will develop, manufacture and supply the products, and ... its own label.  The drugs, comprised of four ...
Breaking Medicine Technology:MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 2MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 3Medtronic - Covidien: Beyond Taxes, Deal Will Create Patient Monitoring Power, according to Kalorama Information 2Medtronic - Covidien: Beyond Taxes, Deal Will Create Patient Monitoring Power, according to Kalorama Information 3Breckenridge Pharmaceutical signs Multi-Product Generic Agreement with Pharmaceutics International, Inc. 2
... , WILMINGTON, Del., Oct. 16 AstraZeneca ... and Drug Administration (FDA) approved CRESTOR® (rosuvastatin calcium) ... familial hypercholesterolemia (HeFH) when diet therapy fails to reduce ... characterized by high LDL cholesterol (the "bad" cholesterol) and ...
... CITY, Oct. 15 Dynatronics Corporation (Nasdaq: DYNT ) ... a letter from Nasdaq stating that the Company has not ... from Nasdaq. , Nasdaq provides the Company an opportunity to ... panel is authorized to grant up to 180 additional calendar ...
Cached Medicine Technology:U.S. Food and Drug Administration Approves CRESTOR(R) for Use in Pediatric Patients With Heterozygous Familial Hypercholesterolemia 2U.S. Food and Drug Administration Approves CRESTOR(R) for Use in Pediatric Patients With Heterozygous Familial Hypercholesterolemia 3U.S. Food and Drug Administration Approves CRESTOR(R) for Use in Pediatric Patients With Heterozygous Familial Hypercholesterolemia 4
(Date:11/26/2014)... The family foundation of Best Buy founder, ... Research Foundation (Meso Foundation), half of which will be ... Grant Program . The focus area of the Richard ... with organizations that can generate transformational results in education, ... founder and chairman emeritus of Best Buy Co., Inc., ...
(Date:11/26/2014)... German scientists say carbon-based synthetic molecules used in ... looks and acts similar to asbestos-induced mesothelioma. Surviving Mesothelioma ... Click here to read it now. , ... Medicine in Hannover injected 500 lab rats with multi-walled ... developed mesothelioma , how quickly it developed appeared ...
(Date:11/26/2014)... Los Angeles, CA (PRWEB) November 26, 2014 ... Los Angeles orthopedic surgeon Dr. Steven Meier has ... site to offer current and prospective patients an online ... , “We’re really excited to present the new and ... and added features make it easier than ever for ...
(Date:11/26/2014)... 2014 ISI Telemanagement Solutions, Inc., ... been award the 2014 Lync Pioneer Award ... comes as a great honor to ISI, who ... ecosystem. Specifically, ISI offers an integrated collaboration reporting ... communication, including voice, video, Lync IM, and conferencing. ...
(Date:11/26/2014)... 26, 2014 For those with a New ... LES MILLS BODYPUMP™ classes at the University of Colorado ... they've been looking for. The 45- 60 minute classes have ... and Wellness Center fitness club memberships. , LES MILLS BODYPUMP™ ... fast-paced and are aimed at fast results , By ...
Breaking Medicine News(10 mins):Health News:Best Buy Founder’s Family Foundation Donates $100,000 to Organization Fighting Deadly Cancer 2Health News:Best Buy Founder’s Family Foundation Donates $100,000 to Organization Fighting Deadly Cancer 3Health News:Multi-walled Nanotubes Linked to Mesothelioma in New Study, According to Surviving Mesothelioma 2Health News:Los Angeles Orthopedic Surgeon Dr. Steven Meier Announces Relaunch Of Practice Website 2Health News:ISI Telemanagement Solutions, Inc. has been Awarded the 2014 Microsoft Lync Pioneer Award 2Health News:LES MILLS BODYPUMP™ classes come to the University of Colorado Anschutz Health and Wellness Center 2
... found that primitive immune systems of fruit flies may ... that immune memory was not possible for insects. ... Medicine could have implications for new ways of developing ... ,The evidence that a fruit fly's immune ...
... Human embryonic stem cells (hESCs) hold great promise for ... provide evidence// that stem cell-derived nerve cells may integrate ... ,This study was conducted by an international collaboration led ... a member of his lab, Jean-Pyo Lee, Ph.D., of ...
... TVs contain possibly hazardous chemicals called polybrominated diphenyl ethers ... of Standards and Technology and the Environmental Protection Agency ... not yet clear how dangerous these PBDEs are, though ... Their structure is strikingly similar to that of PCBs, ...
... risk of prostate cancer amongst Japanese men by as much ... ,"To our knowledge, this is the first prospective study to ... in Japanese, whose intake of soy food is high," wrote ... ,Over half a million news cases of prostate cancer ...
... team of scientists who have achieved a major breakthrough in ... cancer// tumors in humans. ,Anindya Bagchi, along with ... (CSHL), a private research institute in Long Island, New York, ... cells to misbehave and tumors to form. ,The ...
... Unprocessed cocoa is reported to have huge health benefits ... anesthesia//. This was disclosed by Norman Hollenberg, professor of ... suggests that Epicatechin which is found in high levels ... four major and common diseases of the western world ...
Cached Medicine News:Health News:Flies too Have Immune Memory! 2Health News:Flies too Have Immune Memory! 3Health News:Stem Cells Hold Promise for Treating Neurodegenerative Diseases 2Health News:Stem Cells Hold Promise for Treating Neurodegenerative Diseases 3Health News:Stem Cells Hold Promise for Treating Neurodegenerative Diseases 4Health News:Stem Cells Hold Promise for Treating Neurodegenerative Diseases 5Health News:Soy Isoflavones Linked to Lower Prostate Cancer Risk 2
Nitinol Tipless Stone Basket...
1.5 Fr Nitinol Tipless Stone Basket...
Rapid latex agglutination test for presumptive identification of E. coli serogroup O157:H7 isolates. Colorimetric with red O157 latex and blue H7 latex....
For presumptive identification of Escherichia coli using enzyme technology. Tests: Indole, MUG...
Medicine Products: